Evidence map›Paper›PMID 36991096›Full record

ArticleScientific reports2023

Efficacy of elotuzumab for multiple myeloma in reference to lymphocyte counts and kappa/lambda ratio or B2 microglobulin.

Yutaka Shimazu, Junya Kanda, Satoru Kosugi, Tomoki Ito, Hitomi Kaneko, Kazunori Imada, Yuji Shimura, Shin-Ichi Fuchida, Kentaro Fukushima, Hirokazu Tanaka and 22 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.7field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

32 authors at 18 institutions in 1 country.

Yutaka ShimazuDepartment of Hematology and Oncology Graduate School of Medicine, Kyoto University, 54, Kawaramachi, Shogoin, Sakyoku, Kyoto, 606-8507, Japan.
Junya KandaDepartment of Hematology and Oncology Graduate School of Medicine, Kyoto University, 54, Kawaramachi, Shogoin, Sakyoku, Kyoto, 606-8507, Japan. jkanda16@kuhp.kyoto-u.ac.jp.
Satoru KosugiDepartment of Internal Medicine (Hematology), Toyonaka Municipal Hospital, Toyonaka, Japan.
Tomoki ItoFirst Department of Internal Medicine, Kansai Medical University, Hirakata, Japan.
Hitomi KanekoDepartment of Hematology, Japanese Red Cross Osaka Hospital, Osaka, Japan.
Kazunori ImadaDepartment of Hematology, Japanese Red Cross Osaka Hospital, Osaka, Japan.
Yuji ShimuraDivision of Hematology and Oncology, Department of Medicine, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Shin-Ichi FuchidaDepartment of Hematology, Japan Community Health Care Organization Kyoto Kuramaguchi Medical Center, Kyoto, Japan.
Kentaro FukushimaDepartment of Hematology and Oncology, Osaka University Graduate School of Medicine, Suita, Japan.
Hirokazu TanakaDepartment of Hematology and Rheumatology, Kindai University Faculty of Medicine, Higashiōsaka, Japan.
Satoshi YoshiharaDivision of Hematology, Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya, Japan.
Kensuke OhtaHematology Ohta Clinic, Shinsaibashi, Japan.
Nobuhiko UoshimaDepartment of Hematology, Japanese Red Cross Kyoto Daini Hospital, Kyoto, Japan.
Hideo YagiDepartment of Hematology and Oncology, Nara Prefecture General Medical Center, Nara, Japan.
Hirohiko ShibayamaDepartment of Hematology, National Hospital Organization Osaka National Hospital, Osaka, Japan.
Ryosuke YamamuraDepartment of Hematology, Osaka Saiseikai Nakatsu Hospital, Osaka, Japan.
Yasuhiro TanakaDepartment of Hematology, Japanese Red Cross Wakayama Medical Center, Wakayama, Japan.
Hitoji UchiyamaDepartment of Hematology, Japanese Red Cross Kyoto Daiichi Hospital, Kyoto, Japan.
Yoshiyuki OndaDepartment of Hematology, Japanese Red Cross Takatsuki Hospital, Takatsuki, Japan.
Yoko AdachiDepartment of Internal Medicine, Japan Community Health Care Organization Kobe Central Hospital, Kobe, Japan.
Hitoshi HanamotoDepartment of Hematology, Kindai University Nara Hospital, Ikoma, Japan.
Ryoichi TakahashiDepartment of Hematology, Omihachiman Community Medical Center, Omihachiman, Japan.
Mitsuhiro MatsudaDepartment of Hematology, PL General Hospital, Tondabayashi, Japan.
Takashi MiyoshiDepartment of Hematology, Uji Tokushukai Hospital, Uji, Japan.
Teruhito TakakuwaDepartment of Hematology, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan.
Masayuki HinoDepartment of Hematology, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan.
Naoki HosenDepartment of Hematology and Oncology, Osaka University Graduate School of Medicine, Suita, Japan.
Shosaku NomuraFirst Department of Internal Medicine, Kansai Medical University, Hirakata, Japan.
Chihiro ShimazakiDepartment of Hematology, Japan Community Health Care Organization Kyoto Kuramaguchi Medical Center, Kyoto, Japan.
Itaru MatsumuraDepartment of Hematology and Rheumatology, Kindai University Faculty of Medicine, Higashiōsaka, Japan.
Akifumi Takaori-KondoDepartment of Hematology and Oncology Graduate School of Medicine, Kyoto University, 54, Kawaramachi, Shogoin, Sakyoku, Kyoto, 606-8507, Japan.
Junya KurodaDivision of Hematology and Oncology, Department of Medicine, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Kindai University · JPKyoto University · JPKansai Medical University · JPKyoto Medical Center · JPKyoto Prefectural University of Medicine · JPOsaka Hospital · JPOsaka University · JPTokyo Metropolitan University · JPHyogo Medical University · JPJapanese Red Cross Society Kyoto Daini Hospital · JPJapanese Red Cross Society Wakayama Medical Center · JPKobe Central Hospital · JPKyoto first Red Cross hospital · JPNara Medical University · JPOsaka National Hospital · JPSaiseikai Nakatsu Hospital · JPTakatsuki Red Cross Hospital · JPToyonaka Municipal Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Novel therapeutic drugs have dramatically improved the overall survival of patients with multiple myeloma. We sought to identify the characteristics of patients likely to exhibit a durable response to one such drug, elotuzumab, by analyzing a real-world database in Japan. We analyzed 179 patients who underwent 201 elotuzumab treatments. The median time to next treatment (TTNT) with the 95% confidence interval was 6.29 months (5.18-9.20) in this cohort. Univariate analysis showed that patients with any of the following had longer TTNT: no high risk cytogenic abnormalities, more white blood cells, more lymphocytes, non-deviated κ/λ ratio, lower β

Indexed as

Multiple MyelomaAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy Protocolsbeta 2-MicroglobulinHumansLymphocyte CountProspective StudiesAntibodies, Monoclonal, Humanizedbeta 2-Microglobulinelotuzumab

Identifiers

PMID36991096
PMCPMC10060246
OpenAlexW4361200023

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.